Latest Industry Insights

To learn more about the CMU Cloud Lab, the motivation behind the project and the benefits it will bring, Technology Networks spoke to Rebecca Doerge, PhD, dean, Mellon College of Science, Carnegie Mellon University, and Toby Blackburn, head of business development and research, Emerald Cloud Lab.

The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm³ from a blood sample in as little as fifteen minutes.

This article explores how the expanded use of systematic, collaborative registries should allow the medical device, pharmaceutical and oncology communities to gain additional momentum on the road toward personalized cancer care.

In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.

The service will enable oncologists, hematologists and other healthcare professionals to undertake rapid and extensive genomic analysis of cancer samples on an unprecedented scale in the UK.

An interview with LARVOL’s Sabrina Bellisario and Dr. Mark Gramling helps provide insights into the importance of precision medicine databases and how LARVOL is providing access to the information pharma and biotech companies need as they develop cancer treatments.

Certara is developing biosimulation and tech-enabled approaches to help scientists answer key questions at various stages of the development pipeline, serving to inform and accelerate the path to regulatory approval. One such approach, the company’s Vaccine Simulator™, can be leveraged across different therapeutic areas to determine optimal vaccine dosing and dosing regimens for different patient cohorts.

Technology Networks recently spoke with Dr. Marvin Ouyang, Cyagen’s executive vice president and chief scientific officer, to learn more about humanized mice and the applications they can benefit. In this interview Dr. Ouyang also explains how humanized mice can be generated and highlights some of Cyagen’s capabilities in this area.

Technology Networks recently spoke with Brian Kirk, BioDot’s vice president of business development, to learn more about FISH, its advantages and applications. In this interview, Brian also highlights how new technology is tackling some of the limitations of classical FISH to bring the technique into the 21^st century.

Despite small molecule research spanning many fields, the characterization and identification protocols are often not as good as they should be. We spoke to Andreas Huhmer from Thermo Fisher Scientific to learn how the company's latest mass spectrometer helps address these issues.